35 results about "Gentisic acid" patented technology

Vitamin E conjugates, methods for their preparation, and compositions that include the conjugates. The vitamin E conjugates include a tocopherol moiety covalently coupled through a linker moiety to either a pyroglutamate moiety, a pyrrolidinone moiety, or a gentisic acid moiety.

The invention relates to a method for fast and high-efficient determination of 13 phenolic acids in grape wine, belonging to the technical field of analysis of flavor substances in the grape wine. According to the method disclosed by the invention, ultra-performance liquid chromatography is utilized for performing qualitative and quantitative analysis on phenolic acid substances in the grape wine, and the method specifically comprises the following steps: selecting a BEHC18 chromatographic column, taking 2% acetic acid water and methanol as a mobile phase, setting the flow rate at 0.3mL / min, performing ultraviolet detection on wavelength to get the result that the wavelength of gentisic acid is 320nm and the wavelength of the remainder is 280nm, setting the column temperature at 50 DEG C, setting the sample injection quantity at 1 mu L, and quantifying by a peak area external reference method; and by adopting the method, the detection and the analysis can be simultaneously performed on the 13 phenolic acids in the grape wine within 10min. According to the method disclosed by the invention, any sample pretreatment is not required, and the loss caused by the pretreatment can be avoided; and compared with traditional HPLC (high-performance liquid chromatography), by adopting the method disclosed by the invention, more phenolic acid type compounds can be simultaneously detected, the separation effect is good, the analysis process is greatly shortened, convenient and easy to operate, the detection efficiency is greatly improved and the cost of the mobile phase is saved. The method disclosed by the invention has important significance for further system research of the flavor substances in the grape wine and improvement of the quality of the grape wine.

The present invention relates to stabilised <99m>Tc radiopharmaceutical compositions, which include both a radioprotectant and one or more antimicrobial preservative(s), and hence have an extended lifetime of use. The radioprotectant is ascorbic acid, para-aminobenzoic acid, gentisic acid or a salt thereof with a biocompatible cation, and the antimicrobial preservative is one or more compound from the paraben series of preservatives. The invention is particularly useful for cationic, lipophilic <99m>Tc heart imaging agents such as Myoview(TM).

The invention discloses a marine heavy-duty anti-corrosion coating and a preparation method thereof. The coating comprises the following components in parts by weight: 5-15 parts of mica powder, 10-15 parts of B-N ligand polyaniline / montmorillonite composite conductive material, 8-15 parts of talcum powder, 10-15 parts of quartz powder, 30-40 parts of matrix resin, 0-3 parts of pigment, 0.5-1.0 part of defoamer, 0.5-1.0 part of dispersant, 0.5-1.0 part of coalescing agents and 30-40 parts of solvent, wherein the B-N ligand polyaniline / montmorillonite composite conductive material is synthesized by montmorillonite activated and modified by a surfactant, an organic boronic acid, an aniline monomer and double phenolic hydroxyl derivatives; the organic boronic acid is one of a 2-methyl phenyl boronic acid, a 3-methyl phenyl boronic acid, a 4-methyl phenyl boronic acid, a 3,5-dimethylphenylboronic acid, a phenylboronic acid and 4-methoxy benzene boron; the double phenolic hydroxyl derivatives are one of 3,4-gentisic acid methyl ester, 3,4-dihydroxy benzaldehyde and 3,4-dihydroxy benzoic acid ethyl ester. The coating is excellent in corrosion resistance.

The invention belongs to the field of application environment microorganism and agriculture, and discloses gentisic acid dioxygenase as well as a coding gene and application thereof. A gentisic acid dioxygenase gene dsmD has a nucleotide sequence shown in SEQ ID NO.1, the total length of the dsmD is 1053bp, 350 amino acids are coded, and the amino acid sequence of the dsmD is shown in SEQ ID NO.2.The gentisic acid dioxygenase gene is the first gene disclosed to degrade 3-chlorogentic acid, an intermediate metabolite of dicamba, and a protein coded by the gene is capable of carrying out ring-opening degradation on gentisic acid and 3-chlorogentic acid. The gentisic acid dioxygenase provided by the invention can degrade gentisic acid and 3-chlorogentisic acid of 100mg / l within 30min. Therefore, the gentisic acid dioxygenase gene dsmD has a great potential in constructing transgenic crops for degrading dicamba, and the gentisic acid dioxygenase protein DsmD has a good application prospect in degrading dicamba and benzene ring substances.

The invention relates to the field of pollutant controlling, and specifically relates to a vegetable tannin algae inhibitor and a method for inhibiting the overgrowth of algae in eutrophicated fresh water areas. The vegetable tannin algae inhibitor provided by the invention comprises one or more components selected from gentisic acid, ellagic acid, and tannic acid. All the components of the algaeinhibitor can be obtained through artificial synthesizing, and are cheap in price. The preparation method of the complex agent is simple, and has a strong operability. With the algae inhibitor, secondary pollution to the environment is not caused, water areas can be prevented from water bloom, and the stability of aquatic ecosystems can be maintained. With the complex algae inhibitor provided by the invention, over dose of single component can be effectively avoided, such that the damage to the aquatic ecosystems can be prevented, and various degrees of drug resistances gradually generated inalgae caused by long-term and repeated usage of single algae inhibitor can be effectively overcome or retarded. Also, with the algae inhibitor, algae inhibiting capacity and broad spectrum property of the algae inhibitor can be effectively improved.

The invention discloses a nicotine-gentisate complex crystal. A molecular formula of the nicotine-gentisate complex crystal is C7H6O4 C10H16N2; the nicotine-gentisate complex crystal belongs to monoclinic crystal systems and is provided with space groups P21, unit cell parameters alpha and gamma are 90.00 degrees, and a unit cell parameter beta is equal to 112.40 degrees. The invention further discloses a method for preparing the nicotine-gentisate complex crystal and a tobacco product with the nicotine-gentisate complex crystal. The method includes a, placing gentisic acid in a conical flask,adding solvents into the conical flask, further adding distilled water into the conical flask and stirring the gentisic acid, the solvents and the distilled water until the gentisic acid, the solvents and the distilled water are uniformly mixed with one another; b, carrying out light-resistant treatment on the conical flask obtained at the step a, dropwise adding nicotine under a stirring condition and controlling the reaction temperature and the pH (potential of hydrogen); c, filtering solution obtained after reaction is carried out at the step b, allowing the solution to stand still at normal-temperature light-resistant locations and drying the solution to obtain brown viscous liquid; d, placing the brown viscous liquid obtained at the step c at normal-temperature light-resistant locations and allowing crystals to grow so as to obtain brown transparent needle-shaped solid. The tobacco product can be a gum-based chewing tobacco, a mouth tobacco in bags, electronic cigarette liquid ora heating incombustible cigarette.

Muscle relaxant formulations which include one or more quaternary ammonium neuromuscular blocking agents have a reduced tendency for hydrolytic degradation, and therefore a longer shelf life stability, when combined with one or more organic anions having at least six carbon atoms and having a pKa of less than 4.0 (preferably ranging from 0.5 to 3.5). Particularly good results are achieved when using acids of very low solubility in water, such as gentisic acid which is less than 1% soluble at room temperature.

Mew tranilast complexes and new tranilast cocrystais are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.

The invention discloses application of a 2-acetylamino gentisic acid compound with protein tyrosine phosphatase 1B inhibitory activity to preparing an insulin sensitizer. The 2-acetylamino gentisic acid can be used for preparing drugs for treating diabetes, obesity and complications thereof caused by insulin resistance and is obtained by fermenting and separating deep-sea streptomyces sp. 220225.

The invention discloses a compound nanometer preparation for treating the diabetes mellitus type 2 and a preparation method thereof. The compound nanometer preparation for treating the diabetes mellitus type 2 is mainly prepared from, by weight, 8-15 parts of aloe acetylation gulcomannan, 3-6 parts of Cicletanine, 1-2 parts of decanoyl acetaldehyde, 4-8 parts of syringaresinol monoglucoside, 5-20 parts of banana leaf powder, 3-7 parts of grapefruit seed extract, 1-4 parts of sodium ethylene diamine tetracetate, 0.8-2.0 parts of myristic acid, 0.1-0.5 part of syringic acid, 0.1-0.3 part of gentisic acid, 3-10 parts of lysine, 1-3 parts of carotenoid and 0.03-0.1 part of antioxidant. According to the compound nanometer preparation, blood glucose rising is controlled through interaction of various ingredients, the blood pressure and blood fat of a patient suffering from the diabetes mellitus type 2 are adjusted, sufficient nutritional ingredients can be provided for the patient suffering from the diabetes mellitus type 2, the immunity of the patient is improved, diabetes mellitus and arteriosclerosis are relieved, the effect of treating the diabetes mellitus type 2 is remarkable, and the side effect is small.

The invention discloses a medicinal composition for local burn nursing. The medicinal composition comprises caffeic acid, gentisic acid, beta-sitosterol, triclosan, palmitic acid, beta-chitosan, glutamic acid, ethyl acetate, methionine, Chinese medical extract, Chinese medicinal super micropowder and accessories, wherein raw materials of the Chinese medical extract comprise chlorophytum comosum, kalopanax, lonicera pampaninii, barks of Indian quassiawood, licorice, lycopus lucidus, eurya chinensis roots, eucalyptus robusta, pilea lomatogramma hand.-mazz, hibiscus trionum, abutilon indicum, championella sarcorrhiza, folium broussonetiae, bittersweet herb, dischidia minor, green lilies and radishes; raw materials of the Chinese medicinal super micropowder comprise psychotria serpens, whiteflower leadwood roots, rust powder made of iron and acetic acid, henon bamboo juvenile leaves, umbilicaria esculenta, pternopetalum botrychioides, herbs of shiny cinquefoil and passiflora henryi hemsl; the accessories comprise glycerin, sodium alginate, a preservative, an anti-oxidation reinforcing agent, a surfactant, a stabilizer, an isotonic regulator and injection water. According to the medicinal composition, multiple Chinese herbal medicaments are combined, so that the medicinal composition has the effects of clearing heat, removing toxicity, cooling blood, protecting the heart, removing dampness, nourishing yin, reinforcing qi, nourishing blood and resisting bacteria and viruses, and is free of irritation to skin, burn infection can be effectively treated, and wound healing can be accelerated.

Mew tranilast complexes and new tranilast cocrystals are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.

The invention relates to Klebsiella pneumoniae M5a1 gentisic acid 1, 2-bioxygenase gene engineered bacteria construction and uses thereof. Gentisic acid 1, 2-bioxygenase gene engineered bacteria construction method includes: LB medium ,engineered bacteria proliferation and following steps. (1)gentisic acid 1, 2-bioxygenase gene cloning and high expression (2) extraction of gentisic acid 1, 2-bioxygenase preparation of cisethylene dicarboxylic mono-acyl keto acetic acid using gentisic acid 1, 2-bioxygenase gene engineered bacteria. The invention is convenient to operate. Cisethylene dicarboxylic mono-acyl keto acetic acid product purity is high, being suitable for scale production and uses.

The invention discloses high-purity gentisic acid, the purity of the high-purity gentisic acid is greater than or equal to 99.50%, the high-purity gentisic acid comprises gentisic acid, salicylic acid and an impurity A, and the structural formula of the impurity A is shown in the specification. The invention also discloses an application of the high-purity gentisic acid in preparation of an antiviral agent, an antibacterial agent, an analgesic or an antioxidant excipient. The high-purity gentisic acid is prepared through a specific preparation method, the yield of the high-purity gentisic acid can reach 18-22%, and the high-purity gentisic acid is suitable for large-scale industrial production.

The invention discloses an anti-osteoporosis drug, relates to the technical field of research and development of anti-osteoporosis drugs, and particularly relates to an anti-osteoporosis drug. The anti-osteoporosis drug comprises a prepared rehmannia root water extract and main monomer components thereof, namely echinacoside, rehmannioside, verbascoside, scorch-fried rehmannioside, isophenoside, verbascoside, catalpol, rehmannioside A, rehmannioside B, rehmannioside D, Rehmaionoside A, Rehmaionoside B, Rehmaionoside C, rehmanniin A, rehmanniin B, rehmanniin D, rehmanniin C, leonuride, rehmannioside D, geniposide, gentisic acid, apigenin, oleanolic acid, polysaccharide and reducing sugar, and derivatives of the components. In the anti-osteoporosis drug, the prepared rehmannia root water extract can prolong the reaction time of photothermal pain of ovarian estrogen deprived rats, can increase the mechanical touch-induced pain threshold of the ovarian estrogen deprived rats, and can reduce formalin inflammatory pain of the ovarian estrogen deprived rats.

The invention provides application of compounds in preparation of medicines for inhibiting formation and / or growth of calculi, and belongs to the technical field of biological medicine. The compounds are compounds as shown in a formula I or a formula II, or salts thereof, or stereoisomers thereof, or hydrates thereof, or solvates thereof, or prodrugs thereof. Specifically, the compounds are salicylic acid, gentisic acid and succinic acid. Studies find that the salicylic acid, the gentisic acid and the succinic acid can effectively inhibit crystal formation and growth, and can be used as crystal inhibitors for preparing medicines for inhibiting formation and growth of the calculi. Wherein the succinic acid not only has an optimal effect of inhibiting formation and growth of the calculi, but also has a good protection effect on kidneys, and is good in safety. The invention provides a new target and a treatment scheme for intervening in-vivo calculus formation and growth, and has a good application prospect.

The invention provides a compound I liquid composition, a preparation method and application thereof, and the compound I liquid composition is selected from one or more than two of vitamin C, vitamin C sodium and gentisic acid. By optimizing process parameters and the process flow, the method can be suitable for mass production, and the obtained product is high in radiochemical purity, high in activity concentration, good in product stability and high and stable in yield or yield.

The invention relates to novel gentisic acid derivatives (2-hydroxy-5-alkyl (H) oxo benzoates), which have a structural formula shown in the specification, wherein R1 is any one of hydrogen, methyl, ethyl, benzyl and p-nitrobenzyl; and R2 is hydrogen or methyl. The invention also discloses a new application of the novel gentisic acid derivatives (2-hydroxy-5-alkyl (H) oxo benzoates) in the beauty and whitening field. The novel gentisic acid derivatives (2-hydroxy-5-alkyl (H) oxo benzoates) have the advantages of low toxicity, high stability, better pharmacological activity and excellent beauty and whitening effect.

The invention belongs to the field of health-care products, and particularly relates to a pharmaceutical composition containing gentisic acid and application of the pharmaceutical composition. The composition comprises the effective components of the gentisic acid and cabernet sauvignon pomace extract, wherein the mass percentage of the effective components is 0.3-1.2 wt%, and the balance is a pharmaceutically acceptable carrier; and in the effective components, the mass percent ratio of the gentisic acid to the cabernet sauvignon pomace extract is 1: 5. The application of the pharmaceutical composition containing the gentisic acid and the cabernet sauvignon pomace extract is used for treating obesity and related diseases. According to the obtained pharmaceutical composition, the effectivecomponents of the gentisic acid and the cabernet sauvignon pomace extract can effectively inhibit body obesity caused by high-fat and high-sugar diet and improve glucose tolerance and insulin resistance of the body, so that a new treatment way is opened up for treatment of the obesity and related diseases.

The present invention relates to novel co-crystal forms of the compound of formula (I) which is shown in the specification; wherein the co-former molecule is selected from glycolic acid, salicylic acid, decanoic (capric) acid, gentisic acid (2,5-dihydroxybenzoic acid), glutaric acid, vanillic acid (4-hydroxy-3-methoxybenzoic acid), succinic acid, malonic acid or maltol (3-hydroxy-2-methyl-4-pyrone); and to processes for their preparation, to pharmaceutical compositions containing such co-crystals, to the use of such co-crystals in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of a co-crystal of the compound of formula (I).

The present invention relates to salts of a pyrrolopyrimidinone derivative having superior PDE-5 inhibition activity and a process for preparing the same. More particularly, the present invention relates to a crystalline acid addition salt prepared by reacting a pyrrolopyrimidinone derivative with an acid selected from gentisic acid, maleic acid, citric acid, fumaric acid and tartaric acid. With no hygroscopic property and superior long-term storage stability, photostability and thermal stability, the salts of the pyrrolopyrimidinone derivative are appropriate to be prepared into medications and, with superior PDE-5 inhibition activity, are useful for the treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive pulmonary disease, benign prostatic hypertrophy and lower urinary tract diseases.

The invention discloses a pharmaceutical composition for treating alcoholic hepatitis and a preparation method thereof. The pharmaceutical composition is prepared by taking twigs and leaves of murraya kwangsiensis, orchis latifolia herb, aboveground part of clematis aethusifolia, ailanthus pricklyash bark, phospholipid mycin and gentisic acid as raw materials according to a certain proportion, and can be prepared into various dosage forms according to the conventional preparation process. The pharmaceutical composition has a remarkable curative effect on the alcoholic hepatitis.